ABY-251

N/A

Report date: 2025/01/26 18:30:19

Base Information

Drug NameABY-251
Drug Alias Name188Re-ABY-251HER-2-targeted theranostic agent (Affibody Medical/Uppsala University)radiolabeled ABY-251 (Affibody Medical/Uppsala University)[188Re]-ABY-251ABY-251
ClassificationRadiation-emitting products
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUppsala University
China Registration ClassN/A

Develop Information

Active CompaniesAffibody Medical ABUppsala University
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A